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Introduction
Cancer is one of the leading causes of morbidity and mortality worldwide and it is 
expected to become the major cause of death in the coming decades (NIH 2017; WHO 
2017). Cancer is defined as a multifactorial disease involving a malignant growth of tis-
sue (malignant tumour) that possesses no physiological function, and arises from an 
uncontrolled, usually fast, cellular proliferation. The tumour can expand locally in the 
same tissue by cellular invasion and systemically to other organs, a process known as 
metastasis. In cancer, the cellular mechanisms that regulate gene expression and cell 
proliferation are altered, mostly due to mutations of the genetic material or other epige-
netic modifications. The cell type and these alterations are what will mainly determine 
tumour’s growth rate and metastatic potential, and consequently severity. However, 
other factors such as the patient hormone profile or immune system characteristics can 
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be determinant in the individual clinical development of cancer, increasing its intricacy 
and pledging for personalized treatments (Greaves 2000).
Besides, the considerable progress made in understanding the biological and molec-
ular basis of cancer during the past 50  years has not been translated into a notable 
improvement of its incidence and mortality (Kiberstis and Travis 2006), neither in the 
control of treatment-limiting side effects, also contributing to improper treatment com-
pliance (Frenkel 2013). Therefore, efficient cancer therapies still remain elusive. Ideally, 
cancer treatments aim to entirely eliminate all tumour cells, minimizing side effects on 
the rest of the organism. Surgery, radiotherapy, and chemotherapy have been the main 
treatment approaches used in the past decades. Today, along with them, other forms of 
therapy as hormone therapy, immunotherapy, photodynamic therapy and targeted ther-
apies complete the catalogue of treatment modalities used in the clinic to fight cancer.
Cancer resistance mechanisms
The main obstacle for the success of cancer treatment is the development of resistance 
through different mechanisms. Briefly, drug resistance is the reduction in effectiveness 
of a drug such as an antimicrobial or an antineoplastic (antitumoural) agent in curing 
a disease or condition. Based on the initial tumour response to a treatment, mecha-
nisms of cancer resistance can be classified in two categories: (a) intrinsic, which is the 
resistance due to features present in the tumour before the therapy. Consequently, in 
this case, the tumour will be resistant even before being treated. (b) Acquired, which 
is the resistance developed as a response to the selective pressure of the treatment. In 
this case, usually tumour size is initially reduced as the bulk of the tumour is eliminated. 
However, some clones evolve and develop resistance, remain latent until the treatment is 
finished, and then expand to repopulate the tumour (Livney and Assaraf 2013; Thomas 
and Coley 2003). Also, it may happen a combination of both. There are some tumour 
subpopulations that show intrinsic resistance, but as treatment starts it acts as an agent 
exerting selective pressure, and some other populations will acquire resistance de novo. 
In other words, attacking the tumour may train it and make it more robust and resistant, 
as happens with bacteria if the antibiotic treatment is interrupted before completeness 
(Liang et al. 2010).
Disease resilience is a result of genetic diversity. In recent years researchers learned 
that within a single tumour or infection, there is great genetic diversity and variation 
among clusters of cells. This recalls the Darwinian laws of natural selection, the survival 
of the fittest. Diseases related to or produced by life forms, such as cancer, are subjected 
to them. Thus, as medical practice for cancer treatment increases and improves, resist-
ance rises, in an arms race vicious loop.
Recent studies revealed tumour heterogeneity as an important driver for the onset 
of resistance (Hanahan and Weinberg 2011; Nagy and Dvorak 2012; Saunders et  al. 
2012; Yachida et al. 2010; Zhu et al. 2014), which can make the whole tumour as resist-
ant to treatment once the first wave of treatment has eliminated the weak tumoural 
cells, leaving the resistant ones alone. The tumour heterogeneity is the observation of 
the high genetic variation, which is translated into distinct morphological and pheno-
typic profiles, different cell plasticity, metabolism, motility, proliferation activity, and 
metastatic potential of the different cells that constitute the whole tumour. The tumour 
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heterogeneity is critically determined by the microenvironment in which the tumoural 
cells reside (Bissell et  al. 2002; Joyce and Fearon 2015; Levental et  al. 2009; Spill et  al. 
2016; Wiseman and Werb 2002). It is in all this fronts that nanotechnology needs to pro-
vide ways of action.
There are different molecular mechanisms and adaptive responses involved in the 
onset of resistance. Some of these processes are skilful cellular mechanisms that make 
the tumoural cell resistant. Additionally, due to the diversity of genetic populations and 
the microenvironment in a tumour, in other cases it is the tumour tissue that becomse 
resistant. Several mechanisms that make tumoural cells resistant to chemotherapeutic 
treatments have been already identified, such as increased rates of drug efflux, altered 
drug metabolism and target, and repairing mechanisms. In the case of increased drug 
efflux, the overexpression of transporters in the cytoplasmic membrane expels the 
chemotherapeutic agents from the tumoural cell before they can act. The most paradig-
matic and known case is the role of the P-glycoprotein (P-gp), a cell membrane protein 
that acts as an ATP-dependent drug efflux pump, decreasing drug accumulation. The 
P-gp mechanism of action was first described in the work of Juliano and Ling (1976) 
using Chinese hamster ovary cells selected for resistance to colchicine. They found 
that this drug-resistant phenotype displayed a membrane alteration that reduced rates 
of drug permeation, and that the relative amount of P-gp correlated with the degree of 
drug resistance in a number of independent mutant clones. Futher, many other works 
proved the role of P-gp in the appearence of drug resistance (Doyle et al. 1998; Robey 
et al. 2007, 2008).Other mechanisms involve alterations in drug metabolism, thus reduc-
ing drug activity (Kato et  al. 1963; Pao et  al. 2005b; Toffoli et  al. 2010), the mutation 
and alteration of drug targets (Greenman et al. 2007; Pao et al. 2005a), and the activa-
tion and up-regulation of alternative compensatory signalling pathways (Fojo and Bates 
2003; Gottesman et al. 2002; Longley and Johnston 2005). For instance, the up-regula-
tion of oncogenes and the higher DNA repair capacity have been proved to make some 
tumoural cells more resistant to drugs promoting apoptosis (Cantley and Neel 1999; 
Evan and Littlewood 1998; Harris 1996; Zhao et al. 2004).
Many of these mechanisms are not drug-specific and cancer cells are constantly using 
a variety of non-specific tools, involving genes, proteins, and altered pathways, to ensure 
their survival against antineoplastic drugs and treatments. Thus, usually, tumoural cells 
are resistant to drugs of a wide chemical variety, what is known as multidrug resistance 
(MDR) from where over 90% of cancer treatment failures have been attributed to (Gong 
et  al. 2012; Luqmani 2005). Note that the list of mechanisms mentioned above that 
induce the appearance of drug resistance and MDR is not exhaustive and new studies of 
drug resistance mechanisms are constantly appearing, as well as the complex and chal-
lenging ways in overcoming this type of multidrug treatment resistance (Bachas et  al. 
2017; Dlugosz and Janecka 2016; Gao et al. 2015a, b; Higgins 2007; Noll et al. 2017).
In this regard, recently, cancer stem cells (CSC) (alternatively named “tumour-initiat-
ing cells”) have been identified as another source of tumour tissue resistance (Beck and 
Blanpain 2013; Greaves and Maley 2012; Hanahan and Weinberg 2011). CSC were first 
described in the work of Bonnet and Dick (1997) where they showed a cellular popula-
tion capable of initiating human acute myeloid leukaemia in non-obese diabetic mice 
with severe combined immunodeficiency disease. These cells were showed to possess 
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the potential for self-renewal and differentiative and proliferative capacities expected 
for leukaemic stem cells. CSC represent a small population of cancer cells and share 
common properties with normal stem cells. CSC are usually quiescent (as normal stem 
cells) and provided with different characteristics that makes them intrinsically multi-
drug resistant. Mechanisms of action of most of chemotherapeutic agents rely on divid-
ing cells in order to cause lethal damage and induce apoptosis by altering the cell cycle. 
Thus, CSC are less susceptible to therapies. In addition, described different signalling 
pathways contributing to maintain the stemness of CSC, guaranteeing chemotherapy 
resistance, tumour growth, and metastases (Shipitsin and Polyak 2008; Valent et al. 2012; 
Vinogradov and Wei 2012) have been described. Therefore, CSC have been considered 
intrinsically drug resistant, and once the treatment is stopped they have the ability to 
regenerate the tumoural tissue again and again.
Furthermore, the local tumour microenvironment has been shown to decisively con-
tribute to cancer growth, metastasis, and progression to resistance (Bissell et al. 2002; 
Wiseman and Werb 2002). It constitutes the cellular environment in which the tumour 
exists that includes among others the surrounding blood vessels, stromal cells such as 
the fibroblasts, immune cells, and the extracellular matrix and signalling molecules pre-
sent in it. As it happens with normal tissues and the extracellular matrix, the tumour 
and the surrounding microenvironment are closely related and interact constantly. 
Tumoural cells influence the microenvironment by releasing extracellular signals, pro-
moting tumour angiogenesis and inducing peripheral immune tolerance. In turn, the 
immune cells in the microenvironment can affect the growth and evolution of tumoural 
cells. Thus, through this interaction, the production of secreted factors by tumoural cells 
can increase the capacity of the microenvironment to alter the response of the tumour to 
treatment (Iyer et al. 2013; Swartz et al. 2012; Vinogradov and Wei 2012). This surround-
ing tumour area is an appealing target for nanoparticles (NPs) that reach the tumour 
periphery by enhanced extravasation, penetration, and retention effect (Maeda 2001). 
Table 1 shows a summary of the adaptation and resistance mechanisms described in this 
work.
Multimodality
In this scenario, it is accepted that none of the existing single-modality treatments may 
cure cancer. Current anticancer therapies (including chemotherapy, radiotherapy, sur-
gery, hormone therapy, immunotherapy, photodynamic therapy, and targeted therapies) 
are not effective yet in the treatment of tumour resistance (Mi et al. 2012a). Even more, 
as it has been mentioned above, chemotherapy, alone or even in combination with other 
therapies, fails to eradicate CSC clones and instead favour the expansion of the CSC pool 
or select for the MDR resistant cell clones, which ultimately leads to relapse with new 
tumours becoming more malignant (Clappier et al. 2011). Also, radiotherapy and chem-
otherapy may be inefficient when tumour cells are not highly susceptible to them due 
to radio-insensitivity and the MDR intrinsic or acquired by cancer cells (Seiwert et al. 
2007). Thus, improved approaches to overcome tumour resistance are increasingly being 
sought out. To this end, multimodal treatments are being investigated for the possible 
synergistic effects of the combination of different therapies. Multimodality is under-
stood as the mixture of more than one drug and therapies including thermotherapy, 
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radiotherapy, immunotherapy, and gene therapy. Here, the key is to treat cancer as 
something that is not uniform and unchanging; therefore, combined attacks (multimo-
dality) to the target seem the proper approach (Chiang et al. 2010; Lai et al. 2003). This 
Table 1 Description of  the main mechanisms of  cancer resistance, and  treatment 
approaches offered by multifunctional nanoparticles
Resistance mechanism Description NP-based treatment approach
Drug metabolism and drug 
target regulation
Anti‑cancer treatments can induce the up‑
regulation of certain signalling pathways 
in order to develop resistance like ampli‑
fication, drug metabolism or mutation of 
drug targets (Vinogradov and Wei 2012)
Drug protection and drug cocktail
 Drugs can be conjugated with NP 
for drug delivery, which protects 
them from degradation. Further, 
when combining more than one 
drug in a single NP lowers the 
chances of resistance onset
Efflux pumps Drug efflux transporters—first described in 
reference (Juliano and Ling 1976)—in the 
cytoplasmic membrane that expel the 
chemotherapeutic agents from the cell 
are generally found to be overexpressed 
in MDR cancer cells, lowering intracellular 
drug concentration (Kirtane et al. 2013)
Drug cocktail and drug cargo
The local release of (different) drugs 
from the NP increase intracellular 
drug concentration, which can 
saturate the efflux pumps mini‑
mizing their resistance effect
Tumour microenvironment The cellular environment in which the 
tumour exists can alter the response of 
tumour cells to chemotherapy and tar‑
geted therapies. It induces the production 
of secreted factors, which drives tumour 
growth, MDR and metastasis. Also, it cre‑
ates a suitable environment for treatment 
resistance due to the high interstitial 
pressure (impeding drug penetration) and 
hypoxia (up‑regulating other resistance 
signalling pathways) (Iyer et al. 2013; 
Swartz et al. 2012; Vinogradov and Wei 
2012)
Improved tumour penetration
NPs enable local hyperthermia 
which can contribute in (a) 
increasing the blood flow and 
tumour oxygenation, and (b) 
enhancing drug penetration by 
decreasing tumour viscosity
Quiescent phenotypes As conventional chemotherapy agents rely 
on blocking cell division to induce apop‑
tosis, quiescent cells are not affected. Once 
the treatment is stopped, this remaining 
pool of cells can grow to repopulate the 
tumour. A significant tumour subpopula‑
tion displaying this phenotype are CSC, 
which also possess other intrinsic resistant 
properties (Dean et al. 2005)
Radio-enhancement
Radiotherapy and hyperthermia 
are efficient cancer treatments 
irrespective of cellular type. NPs 
act as sensitizers in thermo and 
radio, increasing the local damage 
to kill more resistant cells
Stemness There are several signalling pathways and 
genes involved in CSC maintenance. The 
most studied are Hedgehog, Wnt, Notch, 
and Nanog. Different studies showed 
that they provide the necessary signals to 
remain in the stem cell state to self‑renew, 
to guarantee tumour growth and they 
have also been related to chemotherapy 
resistance and metastases (Vinogradov 
and Wei 2012)
Targeting. Side effects attenuation
(1) NPs can enable targeted 
therapies, which increases local 
damage at the targeted site while 
attenuating side effects in the rest 
of the organism. This reduces side 
effects and allows to fight highly 
resistant cells by (a) increasing 
doses of drugs and/or radiation 
(more aggressive treatment) 
and, (b) combining effects of 
chemotherapy (drug cocktails), 
gene therapy, and radiotherapy 
(overwhelming resistance and 
repairing mechanisms)
(2) Although these are not 
approaches to address these 
specific resistance mechanisms, is 
the NP which enables multimodal 
treatments able to fight against 
them
Apoptosis resistance The up‑regulation of oncogenes and the 
higher DNA repair capacity have been 
proved to make some tumoural cells 
more resistant to apoptosis. Addition‑
ally, the hypoxic microenvironment has 
been found to further induce apoptosis 
resistance, the hypoxia‑inducible factors 
(HIF) up‑regulate the factors of DNA‑repair 
machinery (Milane et al. 2011)
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is because therapeutic effects of the different treatments are designed to add up, while 
their side effects are distributed. Importantly, there is a reduced probability of resistance 
generation in the case of multimodality since drug and therapy cocktails target different 
structures of the tumoural cells and their microenvironment, and have complex action 
mechanisms to which is more difficult to develop resistance.
As the most common reason for acquisition of resistance to a broad range of differ-
ent drugs is the expression of one or more mechanisms that detect, deactivate and eject 
drugs from cells, strategies based on overloading the target with more drugs and thera-
pies are appealing. In addition, side effects avoid this type of approach. In this context, 
multiple drugs loading onto NPs that protect and transport the drug seem a very prom-
ising tool to deliver a cargo of drugs to the target cell, overriding defense mechanisms 
and avoiding side effects. Regarding this last point, while many efforts have been carried 
out looking for increased efficacy of antitumoural agents, the use of NPs to avoid side 
effects allowing for extended therapy has been also demonstrated (Comenge et al. 2012). 
Additionally, the light absorption properties of inorganic NPs can be employed as imag-
ing contrast, radiotherapy*** and thermal therapy agents (Puntes 2016).
Inorganic NPs as scaffolds
To develop multimodality, inorganic NPs are especially suited to combine in a unique 
platform different tumour treatment modalities (Fig.  1). Inorganic NPs are small and 
can, therefore, interact with molecular biological structures in a unique manner (Alivi-
satos 2001). Thus NP-based platforms can be used as scaffolds where the NP is at the 
service of the drug, to transport and to protect it (Chavany et al. 1994; Han et al. 2006). 
Not only they are drug cargos, allowing a high dose of drug to arrive at more delayed and 
intermittent times (Comenge et al. 2012), but also they can modify the biodistribution 
of the drug in the organs, in the tissues and in the cells, while reducing adverse effects 
(Comenge et  al. 2012). The co-administration and co-delivery of different drugs and 
biomolecules such as antibodies and genetic materials with NPs not only contribute to 
Fig. 1 Schematic representation of different cancer treatment modalities that can be integrated in a single 
NP‑based platform
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an improved accumulation of drugs in the tumour but also unify their pharmacokinetic 
profiles and limits drug degradation. Also, the transport of the drug with the proper 
coating of the NP and/or using hollow nanostructures may limit not only systemic deg-
radation of the drugs but also the ejection of drugs from the cells before they act (drug 
efflux) and other drug-detoxifying mechanisms (Garcia-Fernandez et al. 2017; MacDiar-
mid et al. 2009; Meng et al. 2010). All these combinatory effects should overwhelm and 
override the resistance mechanisms of the tumoural cells. For instance, in the work of 
Meng et al. (2010) they used mesporous silica nanoparticles as a platform to deliver both 
doxorubicine and siRNA in drug-resistant cancer cell line (KB-V1 cells). As the used 
siRNA knocks down gene expression of a drug exporter used to improve drug sensitivity 
to chemotherapeutic agents, this dual delivery was capable of increasing drug concen-
tration intracellularly and in the nucleus to levels exceeding that of free doxorubicin or 
the drug being delivered in the absence of siRNA. Other examples of these possibilities 
are in the section of this review “Nanoparticles at work enabling multimodality”.
Indeed it has been postulated that in some cases chemotherapy alone does not kill all 
tumoural cells, but that the dying tumoural cells are recognized by the immune system 
which allows their complete eradication (Apetoh et al. 2007). The immune system plays 
a key role in prevention and elimination of tumours. The immune system can specifically 
identify and eliminate cancerous or pre-cancerous cells by recognizing mutations or 
ligands related to stress, a process known as tumour immune surveillance (Smyth 2007). 
Still, some tumour cells overcome the immune system and expand to develop a whole 
tumour. Thus, the theory of tumour immune surveillance has recently been updated by 
emergence of the newer concept of tumour ‘immunoediting’ (Smyth 2007). The process 
encompasses three steps: (a) elimination corresponds to immunosurveillance; (b) it is 
followed by an equilibrium phase, where tumour cells with reduced immunogenicity are 
selected; (c) finally, the escape is the process where the immunologically sculpted tumour 
expands in an uncontrolled manner in the immunocompetent host (Dunn et al. 2002). 
The remaining immunogenic cancer cells use different mechanisms to evade immune 
elimination. For instance, they can secrete TGF-b or other immunosuppressive factors 
to inhibit cell-mediated immunity of cytotoxic T-lymphocytes (CTLs) and natural killers 
(NK) (Shields et al. 2010; Yang et al. 2010). Other mechanisms rely on the recruitment 
of immunomodulatory cells as T-regulatory cells (Tregs) and myeloid-derived suppres-
sor cells (MDSCs) providing an inmuno-protected area where the tumour can keep on 
growing (Mougiakakos et al. 2010; Ostrand-Rosenberg and Sinha 2009).
The possibilities of the rational control on the functionalization of inorganic NPs 
with biomolecules is particularly important for cancer immunotherapy, the training 
of the immune system to attack the tumour (Fan and Moon 2015; Morgan et al. 2006), 
especially in the case of therapeutic vaccines. Three critical elements are considered to 
be essential in the composition of an effective vaccine: an antigen to trigger a specific 
immune response, an adjuvant able to stimulate the innate immunity, and a delivery 
system to ensure optimal delivery (Reddy et  al. 2006). To obtain the full activation of 
antigen-presenting cells (APCs), the simultaneous action of antigens and adjuvants is 
critical. In this regard, inorganic NPs can help to develop (a) safe and powerful adju-
vants to stimulate the immune system in a non-specific way (Bastus et al. 2009a, b) that 
induces an inflammatory state able to detect the otherwise evading tumours (Fan and 
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Moon 2015; Jarvinen et  al. 2009); and (b) as antigen-presenter platforms (Bachmann 
et al. 1993), by conjugating them to tumour-associated antigens to develop the adaptive 
immune response against it (by boosting the immune response through the aggregation 
and repetition of antigens).
Thus, the possibility of incorporating antigens and adjuvants makes NPs ideal plat-
forms for developing cancer vaccines (Park et  al. 2013; Silva et  al. 2013). In addition, 
chemotherapeutic agents can be loaded into them combining immune, chemo, and 
radio therapy enhancement in a single object. Accordingly, NPs could increase the 
uptake of antigens by dendritic cells (DCs) which results in enhanced immune responses 
against tumour. The group of D. Messmer first demonstrated that the conjugation of 
Hp91 (an already identified immunostimulatory peptide) to poly(d,l-lactic-co-glycolic) 
acid NPs (PLGA-NPs) significantly enhanced the activation of DCs, compared to free 
Hp91 (Clawson et al. 2010). More recently, they tested this system against human epi-
dermal growth factor receptor 2 (HER2)-positive breast cancer cells (Campbell et  al. 
2015). Here, as an effect of higher DCs activation, they observed enhanced activation of 
HER2-specific (CTL) responses, delayed tumour development, and prolonged survival 
of the injected mice. Additionally, it has been reported that liposomal NPs can induce a 
depot effect at the site of injection generating a gradual release of the antigen and, there-
fore, increasing its exposure to the cells of the immune system (Henriksen-Lacey et al. 
2011). This leads to an enhanced APCs recruitment and activation, and also eliminates 
the need for repeated doses of the vaccine.
Another immune-based cancer therapy approach is the use of antibodies for block-
ing signalling pathways (Karapetis et al. 2008). In this particular cases, the instability of 
the exogenous antibodies and their low efficiency calls for nanoconjugation (Bhattacha-
ryya et  al. 2010; Garcia-Fernandez et  al. 2017). Thus by condensing the antibodies on 
top of a NP surface, they are protected from systemic degradation (Prego et al. 2010) as 
their pharmacokinetic profile is altered allowing for improved targeting (Comenge et al. 
2012). Additionally, the use of NP-antibody conjugates has shown a prolonged antibody 
therapy effect by avoiding receptor recycling as well of decreasing the needed antibody 
dose in the case of Cetuxymab-Au NPs conjugates targeting the epidermal growth factor 
receptor (EGFR) of A431 cells (Garcia-Fernandez et al. 2017). Coverage density and ori-
entation of antibodies were strictly controlled to properly evaluate their effects. Results 
showed epithelial growth factor receptor blocking along with their altered trafficking 
signalling effects. The blocking effects of cetuximab were increased and sustained for a 
longer time when associated with the Au NPs (Garcia-Fernandez et al. 2017). Here, the 
use of NP-antibody conjugates also presents some natural advantages: rational design, 
low toxicity, low-cost, and modified and modifiable biodistribution.
Inorganic NPs as actuators
In addition, NPs can be active by themselves since they can be antennas that absorb pho-
tons of determined wavelengths, to which we are transparent. Thus, radiotherapy effects 
can be enhanced in such a way that employed doses can be decreased where only the 
NPs allow the toxic effect, improving localized radiotherapy. In these cases, the coating 
can be at the service of the NPs to transport them to the target site. Inorganic NPs can 
interact with photons of different wavelengths and trigger a variety of physical processes. 
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Due to the high electronic density of inorganic materials, they can absorb strongly 
X-rays and selectively enhance the damage inflicted on tumoural tissue in radiotherapy 
treatments. This is mediated by the fact that these materials absorb strongly the primary 
radiation beam (typically X-rays in the MeV range, although electrons, neutrons, and 
positron are also employed), especially high Z number atoms, and subsequently gener-
ate a cascade of secondary low-energy electrons (LEEs) highly toxic within a very short 
range around the NP (Pimblott and LaVerne 2007). These latter are the main source of 
energy deposition and radiation-induced damage in biological tissue (Sanche 2005). 
Moreover, even below ~ 15 eV, LEEs can efficiently induce molecular fragmentation into 
highly reactive free radicals through dissociative electron attachment reactions (Bou-
daiffa et  al. 2000). Within the complex environment of living cells, these light-matter 
interaction processes can directly affect DNA and other nearby cellular components. 
Additionally, the irradiated metallic NP can be activated producing catalytically free rad-
icals as hydroxyl radicals OH· and hydrogen peroxide  H2O2 among others (Von Sonntag 
2006), which can initiate further reactions and induce oxidative stress and cellular dam-
age (Boudaiffa et al. 2000; Von Sonntag 2006). Thus, heavy atom irradiated NPs can be 
seen as a source of free reactive radicals, as pointed out by Carter et al. (2007) and also as 
a vehicle of direct damage as proposed by Sanche group (Brun et al. 2009).
Recent works studying the effects of Au NPs in combination with radiation in vari-
ous cell lines found a damage enhancement factor between 1.5 and 3.4 times depend-
ing on the size of the NPs (Chithrani et al. 2010), incident energy (Rahman et al. 2014), 
and cell type (Bobyk et al. 2013; Hainfeld et al. 2008). Further studies performed with 
in vivo models found tumour regression and up to 66% increase in the 1-year survival 
when mice were treated with 1.9 nm Au NPs, compared to those non treated with NPs, 
under equal radiation conditions (Butterworth et al. 2010). Additionally, the damaging 
enhancement efficacy of NPs have been shown to improve when biodistribution is con-
trolled by coating them with polyethylene glycol (PEG) (Geng et al. 2014; Liu et al. 2010; 
Zhang et al. 2012), and by conjugating them with targeting molecules as antibodies or 
other radiosensitizers (Wolfe et al. 2015).
Inorganic NPs can be also used in combination with near-infrared (NIR) photons 
(800–1100 nm) both for molecular imaging and selective photothermal therapy (Huang 
et al. 2006). Here, some Au NPs such as Au nanorods (Jana et al. 2001; Nikoobakht and 
El-Sayed 2003) or hollow Au NPs (Gonzalez et al. 2011) present a suitable strong surface 
plasmon resonance absorption in the NIR. This is a region of the light spectrum where 
there is a window of transparency for biological tissues (known as the therapeutic win-
dow) from the overlapping light absorption of water, haemoglobin, and melanin. Thus, 
the possibility to excite in the NIR region allows for both minimization photo damage of 
biological specimens and maximization the penetration depth into the tissue of the exci-
tation light. Other examples include up-converting nanophosphors (UCNPs) (Haase and 
Schafer 2011), which exhibit photon upconversion: two or more incident photons within 
the NIR region are absorbed by the UCNPs and converted into one emitted photon with 
higher energy (Auzel 1973; Ostermayer 1971).
In addition, superparamagnetic NPs offer attractive possibilities to treat cancer by 
inducing hyperthermia (Giustini et al. 2010). Magnetic NPs can be manipulated by exter-
nal magnetic fields which show intrinsic high penetrability into human tissue (McCarthy 
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et al. 2007; Pankhurst et al. 2009). When these NPs are exposed to an alternating mag-
netic field of sufficient strength and frequency, there is a conversion of magnetic energy 
into thermal energy. The heat generated is then transferred to the cells surrounding 
the NPs, what can result in cancer cell death by apoptosis once the local temperature 
exceeds 40 °C and proteins denaturate (Pu et al. 2013; Wust et al. 2002). Several groups 
have shown a significant tumour inhibition during hyperthermia therapy by employing 
 Fe3O4 NPs (Shinkai 2002). Although other heating technologies exist to perform hyper-
thermia (namely, optical heating using lasers and ultrasounds heating), the advantage of 
magnetic hyperthermia is that tumours located virtually anywhere in the human body 
can be treated (Petryk et al. 2013). Moreover, the same NPs can be used both for heating 
and magnetic resonance imaging (MRI) (Jiang et al. 2014).
An increasing body of literature supports the claim that the combination of differ-
ent chemo, thermal, and radio treatment approaches significantly improves their out-
come (Mi et al. 2012a). For instance, mild temperature hyperthermia has been proven 
to enhance sensitization to chemotherapy and radiotherapy through different mecha-
nisms. First, local hyperthermia induces an increase of the blood flow and thus, greater 
concentrations of drugs can be delivered to tumours. Second, it also involves a higher 
oxygenation of the tissue, which further enhances the effect of radiotherapy (Song et al. 
2005). On the other hand, the sequential use of chemotherapy and radiotherapy can 
also increase cancer cells radiosensitazion. The suggested molecular mechanism might 
rely on the effects of the chemotherapeutic drugs, dysregulating of S-phase checkpoints 
and inhibiting of the DNA-damage repair machinery, which potentiates the radiation-
induced DNA damage (Lawrence et al. 2003). As a result, lower doses of radiation can be 
delivered and the side-effects to healthy organs are reduced (Fig. 2).
Nanoparticles at work enabling multimodality
The combinatorial effects of the different therapies above mentioned may be the key for 
fighting resistance to treatment. Table 1 shows a summary of the defence mechanisms’ 
tumoural cells use to develop resistance, and the NP-based approach to simultane-
ously attack those mechanisms. In the literature of the past few years there are several 
Fig. 2 Different advantages enabled by a NP platform for a multimodal approach to address cancer resist‑
ance
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examples of the combination of different therapies in a single NP platform. To our 
knowledge, the first studies showing promising results for multimodal therapy with NPs 
involved the co-delivery of biologically active molecules and drugs (dual chemotherapy). 
Thus, back in 2005, Sengupta et al. (2005) presented nanoparticulate system composed 
of a poly(lactic-co-glycolic acid) (PLGA)—doxorubicin-conjugated polymer core and a 
lipid shell consisting on PEG-distearoylphos-phatidylethanolamine, phosphatidylcho-
line and cholesterol. These NPs were subsequently loaded with combretastatin, a natural 
phenolic compound with capability to cause vascular disruption in tumours, thus com-
bining chemotherapy and anti-angiogenesis therapy with encouraging results.
One year later, Wang et  al. (2006) developed a variation of this previous NP with a 
hydrophobic cholesterol core, to uptake poorly water soluble drugs, and coated with a 
cationic polymer shell, to strongly attach to cell membranes, for the co-delivery of pacli-
taxel and a cytokine, the interleukin 12-encoded plasmid. The in vivo synergistic anti-
cancer effect was demonstrated in a breast cancer model in mice. It showed that the 
tumour growth rate in mice treated with paclitaxel-loaded NP/IL-12-encoded plasmid 
complexes was significantly lower than that in the mice treated with either of the thera-
pies alone (Wang et al. 2006). Apart from this, many other reports and reviews can be 
found easily in the literature highlighting the intense research efforts on this topic (Gao 
et al. 2015b; Kemp et al. 2016; Mi et al. 2012a; Shi et al. 2017; Zhang and Zhang 2016). 
Co-delivery of drugs has shown also better perfomance in overcoming cancer therapy 
resistance. For instance, the cocktail delivered with an acid-degradable core–shell NPs 
(MnSOD siRNA-delivering NPs made of a siRNA/poly(amidoamine) dendriplex core 
and an acid-degradable polyketal shell) was proved in reversing tamoxifen resistance 
(tamoxifen is an oestrogen receptor modulator agent that prevents oestrogen from bind-
ing to the oestrogen receptor and blocks breast cancer cell growth resistance in breast 
cancer (Cho et  al. 2013) and rituximab-coated biodegradable polymer NPs loaded 
with both hydroxychloroquine and chlorambucil were proved to restore the sensitivity 
of chronic myelogenous leukaemia cells to cytotoxic targeted drugs (Mezzaroba et  al. 
2013), among many others.
Following to these ones, other studies started to focus on the co-administration of 
chemotherapy, gene therapy and immune therapy (Liu et  al. 2011, 2014) agents using 
various carriers, which include inorganic NPs, peptides, liposomes, and polymeric NPs 
(Yuan et al. 2016). Regarding the use of inorganic NPs, recently, the study of Wu et al. 
(2017) used Buthionine sulfoxamide (BSO) to inhibit glutathione synthesis and celecoxib 
to down-regulte P-gp expression. Both molecules were co-loaded in polymer/inorganic 
hybrid NPs to form buthionine sulfoximine/celecoxib@biotin-heparin/heparin/cal-
cium carbonate/calcium phosphate NPs (BSO/celecoxib@BNP). A reversal of MDR in 
the drug-resistant cells (MCF-7/ADR) pretreated by the dual-inhibitor loaded NPs was 
observed. Using other nanostructured systems, Gao et al. (2017) developed a pH-sen-
sitive mixed micelles composed of HA and TPG copolymer to overcome MDR. These 
micelles increased intracellular uptake, (via CD44) receptor-mediated endocytosis, and 
further enhanced the drug accumulation in MCF-7/ADR cells and the reduction of the 
mitochondrial potential and ATP levels in cells. The copolymer micelles have been dem-
onstrated to be a potential nanocarrier to overcome tumour MDR (Gao et al. 2017).
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Similarly, many examples can be found on the advantages presented of the use inor-
ganic NPs for dual-modality therapy of cancer such as chemotherapy and photodynamic 
therapy. For instance, Peng et al. (2009) used photosensitizing block copolymers and the 
SN-38 antitumoural drug in human colon cancer models. In the study of Liu et al. (2011) 
combination of chemotherapy and thermotherapy was carried out in docetaxel loaded 
PEGylated gold nanoshells on silica nanorattles for the ablation of hepatocellular carci-
noma. Overcoming resistance with this dual (chemo and thermo) therapy has been also 
observed using trastuzumab-conjugated  SiO2@AuNPs in trastuzumab-resistant breast 
cancer cells (Carpin et al. 2011), among many others (Yuan et al. 2016). More recently, 
Kievit et al. (2015) developed a NP-based siRNA delivery system comprised by a super-
paramagnetic iron oxide core (for magnetic hyperthermia) coated with chitosan, PEG, 
and PEI. This system knocked down Ape1 expression over 75% in medulloblastoma cells 
and ependymoma cells, and produced threefold greater sensitivity to ɣ-rays through 
synergetic effects.
Examples of combination of ionizing radiotherapy with other treatment modalities 
integrated in a single NP platform include, for instance, the study of Liu et  al. (2015) 
that developed a core–shell nanostructure comprised by an upconversion NP core and 
mesoporous silica as the shell. The former acted as radiation dose amplifier, and the lat-
ter provides protection to the hypoxia-activated prodrug, tirapazamine (TPZ), which 
was loaded within the cavity between the core and shell. These NPs showed low cyto-
toxicity and high in vivo biocompatibility. As radiosensitizers, the TPZ-filled NPs exhibit 
a greatly enhanced cytotoxicity and anti-tumour efficacy, both in  vivo and in  vitro, 
compared with either free TPZ or RT alone. The group of Shi et  al. (Fan et  al. 2013) 
also reported a multifunctional up-conversion core/porous silica shell NPs loaded 
with cisplatin. In vitro and in vivo studies demonstrated an enhanced efficacy via syn-
ergetic chemo-/radiotherapy. Moreover, this system serves also as a diagnostic agent 
as it allowed simultaneous magnetic/luminiscent dual-mode imaging. An alternative 
approach to counteract radiation resistance is using siRNA to target related pathways. 
For instance, Nawroth et  al. (2010) synthesized chitosan/siRNA NPs targeting TNFα 
and showed that administration of this complex completely prevented radiation-induced 
fibrosis in CDF1 mice, allowing for higher therapeutic doses.
Less examples are found for triple-modality cancer treatment strategies. Shi group fur-
ther developed their up-conversion core/porous silica shell system by allowing the co-
delivery of the radio-/photo-sensitizer haematoporphyrin (HP) and the radiosensitizer/
chemodrug docetaxel (Fan et al. 2014). In vivo experiments showed the complete elimi-
nation of the tumour upon NIR and X-ray irradiation through synergetic chemo-/radio-/
photodynamic therapy (Fan et al. 2014). Also, Mi et al. employed herceptin (immuno-
therapy) conjugated poly-lactic acid polymer NPs loaded with docetaxel (chemotherapy) 
and iron oxide NPs (thermotherapy) for the treatment of HER-2 positive breast cancer 
with encouraging results (Mi et al. 2012b).
Interestingly, the above-mentioned materials can be fused together in the same multi-
meric NP and thus  Fe3O4 domains can be grown onto Au domains to combine magnetic 
and optical detection and excitation (Fantechi et al. 2017).
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The remaining challenge
As described in this review, nanoscale agents have been under intense research and 
exploited to enhance the delivery of drugs in the treatment of a number of diseases 
showing potential benefits in terms of pharmaceutical flexibility, selectivity, dose reduc-
tion, and minimization of adverse effects. Inorganic materials can also be used as 
imaging and radiotherapy agents demonstrating that NP-based therapies can act as “pre-
cision medicine” for targeting tumours and infections while leaving healthy tissue intact. 
However, despite the tremendous potential of nanomedicine and hundreds of millions 
(if not billions) poured from funding institutions, it could be acknowledged that little 
progress has been made towards matching expectations: while scientific community 
keep on trying new nanosized constructs in animal models looking for therapeutic effi-
cacy, little progress is made towards proper knowledge of the processes involved, and 
if very promising results have been observed many times, it is irresponsible to imagine 
that it will be possible to master nanomedicine without a proper knowledge of the physi-
cal and chemical evolution of NPs inside living bodies. Recently, Derek Lowe’s comment 
on drug discovery and the pharma industry in the Science Magazine Blog (Lowe 2016), 
commenting on the nature materials paper analysis of NPs delivery to tumours (Wil-
helm et al. 2016), recognized “Working out that delivery and pharmacokinetics aspects 
of these NPs was already known to be a challenge, but it’s proven to be even more of one 
than anybody thought” (Lowe 2016). Therefore, the following aspects of nanopharma-
cokinetics: what does the body to the NP rather than what does the NP to the body, and 
the consequences that this entails for the body and the NP are a key enabling-knowl-
edge. Thus, the understanding of the precise evolution of imaging, irradiating, and deliv-
ery nanoplatforms inside the human body is a pressing need sine qua non to develop 
nanomedicine. Otherwise, we may face another decade of witchcraft where marvellous 
things with NPs are observed in the lab but never translated into the clinic to improve 
patient quality and expectation of life.
Thus, to enable the use of NPs in medicine, nanopharmacokinetics (ADME studies 
but adapted to NP characteristics) is needed. NPs evolve as they enter inside the body 
and body compartments, where the final working units are different from what was ini-
tially designed and produced. Consequently, it is necessary to understand the physico-
chemical transformations and evolution of NPs inside biological systems in order to 
enable NPs to work precisely for medicine, understanding the mechanisms of action. It 
is being accepted that NPs may be destabilized when travelling through different parts 
of the body (Casals et al. 2008). Their high surface energy tend to aggregate them homo-
geneously (forming polycrystalline particles) or heterogeneously (with molecules and 
structures of the surroundings), both altering and modifying biodistribution. Similarly, 
during their time inside the body, the presence of different redox states (from rather 
reducing to clearly oxidizing), pH (the late endosome can go down to 5) and the pres-
ence of nucleophilic species and ionic scavengers, alter NP valence state and promote 
NP dissolution, especially in the small size range (Auffan et al. 2009). Inside the body, the 
protein absorption onto NP surface may not only modify NP surface properties but also 
result into protein changes (Goy-Lopez et al. 2012) and could alter their metabolization. 
The consequences of this change in the protein conformation and metabolization in, for 
example, the immune response, are still rather unknown.
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The proper knowledge of the NPs physico-chemical state at all times of its evolution 
inside living bodies comprises among others the colloidal stability, vicinity interac-
tions, chemical transformations-as corrosion-, association with plasma proteins-protein 
corona (PC)-, interaction with components of the immune system, and all the traditional 
ADME studies (administration, distribution, metabolization, and excretion of drugs 
from the body) but adapted to the unique NPspecificities. This knowledge will enable 
to effectively design, produce and monitor the biological work of NPs and it will finally 
unleash nanomedicine potential.
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